HLD-0915对转移性cast割前列腺癌(MCRPC)的患者的研究
HLD-0915的1/2阶段研究在转移性cast割前列腺癌(MCRPC)的患者中
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Study Contact
- 电话号码:844-434-4210
- 邮箱:Participate-In-This-Study1@its.jnj.com
学习地点
-
-
Colorado
-
Colorado Springs、Colorado、美国、80909
- 招聘中
- Rocky Mountain Cancer Center
-
Denver、Colorado、美国、80218
- 招聘中
- Sarah Cannon Research Institute 1
-
-
Connecticut
-
New Haven、Connecticut、美国、06511
- 招聘中
- Yale University
-
-
Florida
-
Sarasota、Florida、美国、34232
- 招聘中
- Florida Cancer Specialists
-
-
Louisiana
-
Metairie、Louisiana、美国、70006
- 招聘中
- XCancer Research Network LCMC Health EJGH
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Dana Farber Mass General Brigham Cancer Care Inc
-
-
Michigan
-
Grand Rapids、Michigan、美国、49546
- 招聘中
- South Texas Accelerated Research Therapeutics, LLC (START)
-
-
Nebraska
-
Omaha、Nebraska、美国、68130
- 招聘中
- Urology Cancer Center, PC
-
-
New York
-
Long Island City、New York、美国、11101
- 招聘中
- Memorial Sloan Kettering Cancer Center
-
Syracuse、New York、美国、13210
- 招聘中
- Associated Medical Professionals
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University Medical Center
-
-
South Carolina
-
Myrtle Beach、South Carolina、美国、29572
- 招聘中
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Sarah Cannon Research Institute
-
Nashville、Tennessee、美国、37209
- 招聘中
- Urology Associates
-
-
Texas
-
Austin、Texas、美国、78758
- 招聘中
- NEXT Oncology
-
Houston、Texas、美国、77030
- 招聘中
- MD Anderson Cancer Center
-
-
Virginia
-
Norfolk、Virginia、美国、23502
- 招聘中
- Virginia Clinical Research
-
-
-
-
-
Sutton、英国、SM2 5PT
- 招聘中
- The Royal Marsden NHS Trust
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Patients must meet the following criteria to be eligible study participation:
Key Inclusion Criteria:
All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication
mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen
SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI
mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL
Key Exclusion Criteria:
All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition
mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods
SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer
mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:JNJ-101556143 Phase 1 Part 1 - Dose Escalation
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
实验性的:JNJ-101556143 Phase 1 Part 2 - Formulation Exploration
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 |
|
实验性的:JNJ-101556143 Phase 2 Part 1 - Dose Optimization
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
实验性的:Phase 2 Part 2A - SOAR
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
实验性的:Phase 2 Part 2B - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
实验性的:Phase 2 Part 2C - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
实验性的:Phase 2 Part 2D - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Frequency of dose-limiting toxicities (DLTs)
大体时间:21 days
|
21 days
|
|
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
大体时间:21 days
|
21 days
|
|
Phase 1 Part 2 (formulation exploration) relative bioavailability
大体时间:22 days
|
22 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PK Parameters
大体时间:21 days
|
21 days
|
|
|
Duration of Response (DOR)
大体时间:21 days
|
21 days
|
|
|
Radiographic Progression-Free Survival (rPFS)
大体时间:63 days
|
63 days
|
|
|
Time to Response (TTR)
大体时间:63 days
|
63 days
|
|
|
Change in PSA over time
大体时间:21 days
|
Including PSA50 and PSA90 response |
21 days
|
|
Objective Response Rate (ORR)
大体时间:63 days
|
Per RECIST in evaluable patients |
63 days
|
合作者和调查者
调查人员
- 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- HLD-0915-ONC-101
- HLD-0915-ONC-101 (其他标识符:Janssen Research & Development, LLC)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.